Loading…
Reported covered position: Policy Advisor, Office of Richard Gephardt | Senior Legislative Assistant, Office of Bart Stupak
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2023 · third_quarter · Q3
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Source: Senate LDA
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
American Innovation and R&D Competitiveness Act of 2023
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to Medicare Part D redesign. H.R. 2673, The American Innovation and R&D Competitiveness Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act
Speeding Therapy Access Today Act of 2021
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Speeding Therapy Access Today Act of 2021
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Speeding Therapy Access Today Act of 2021
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Elijah E. Cummings Lower Drug Costs Now Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
- Issues related to the development of therapies for rare diseases. - Build Back Better Act (H.R. 5376) - CURES 2.0 Act (H.R. 6000) - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
- Issues related to the development of therapies for rare diseases. - Build Back Better Act (H.R. 5376) - CURES 2.0 Act (H.R. 6000) - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Accelerated Approval Integrity Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Accelerated Approval Integrity Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Accelerated Approval Integrity Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Accelerated Approval Integrity Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Orphan Drug COVID–19 Mitigation Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Orphan Drug COVID–19 Mitigation Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Orphan Drug COVID–19 Mitigation Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Speeding Therapy Access Today Act of 2021
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Speeding Therapy Access Today Act of 2021
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Speeding Therapy Access Today Act of 2021
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
- Issues related to the development of therapies for rare diseases. - Build Back Better Act (H.R. 5376) - CURES 2.0 Act (H.R. 6000) - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
Elijah E. Cummings Lower Drug Costs Now Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
- Issues related to the development of therapies for rare diseases. - H.R. 3 Lower Drug Costs Now Act - CURES 2.0 Act discussion draft - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
Elijah E. Cummings Lower Drug Costs Now Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
- Issues related to the development of therapies for rare diseases. - H.R. 3 Lower Drug Costs Now Act
- Issues related to the development of therapies for rare diseases. - Build Back Better Act (H.R. 5376) - CURES 2.0 Act (H.R. 6000) - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
- Issues related to the development of therapies for rare diseases. - H.R. 3 Lower Drug Costs Now Act - CURES 2.0 Act discussion draft - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
- Issues related to the development of therapies for rare diseases. - Build Back Better Act (H.R. 5376) - CURES 2.0 Act (H.R. 6000) - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
- Issues related to the development of therapies for rare diseases. - H.R. 3 Lower Drug Costs Now Act - CURES 2.0 Act discussion draft - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
- Issues related to the development of therapies for rare diseases. - Build Back Better Act (H.R. 5376) - CURES 2.0 Act (H.R. 6000) - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2023 · second_quarter · Q2
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2023 · first_quarter · Q1
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act.
Issues related to Medicare Part D redesign. H.R. 2673, The American Innovation and R&D Competitiveness Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2022 · fourth_quarter · 4A
Issues relating to Research and Development Tax Amortization.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2022 · fourth_quarter · Q4
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2022 · third_quarter · Q3
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2022 · second_quarter · Q2
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2022 · first_quarter · Q1
- Issues related to the development of therapies for rare diseases. - Build Back Better Act (H.R. 5376) - CURES 2.0 Act (H.R. 6000) - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2021 · fourth_quarter · Q4
- Issues related to the development of therapies for rare diseases. - Build Back Better Act (H.R. 5376) - CURES 2.0 Act (H.R. 6000) - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2021 · third_quarter · Q3
- Issues related to the development of therapies for rare diseases. - H.R. 3 Lower Drug Costs Now Act - CURES 2.0 Act discussion draft - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2021 · second_quarter · Q2
- Issues related to the development of therapies for rare diseases. - H.R. 3 Lower Drug Costs Now Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2021 · first_quarter · Q1
Issues related to the development of therapies for rare diseases.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE